Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04476433
Other study ID # FACTORADAPT
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 4, 2019
Est. completion date December 30, 2023

Study information

Verified date March 2024
Source University of Valencia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project consists of a psychological intervention in patients and their families with different chronic diseases in order to carry out a comparative study between medical pathologies to know which are the protective or risk variables for the adaptation to the disease.


Description:

Adolescence is a period characterized by a multitude of changes at the biopsychosocial level, all of which also implies many challenges. If the diagnosis or the presence of a chronic disease or condition (CD) is added, the adjustment of the adolescent to this period become even more difficult. The World Health Organization (WHO) (2017) defines chronic diseases (CD) as "long-lasting and usually slow-progressing diseases". Among the main child-juvenile CDs are the allergic, the endocrine; in particular, Diabetes Mellitus Type 1 (DM1) and Short stature (SS), and respiratory, such as bronchial asthma (BA). Chronic pediatric disease is a medical condition that affects both the patient and the family caregiver. Chronic disease is characterized by unforeseeable changes in the course of the disease, a reduction in physical capacity, changes in appearance, a prolonged dependence on medical specialists, continuous treatments and the need for assistance. The presence of CD in adolescence is a risk factor for developing a psychological disorder. The most common psychopathology in childhood-juvenile CD is emotional, particularly anxiety symptoms, followed by depression symptoms, being possible the development of an anxiety disorder or of a major depression. When someone is diagnosed with a chronic disease, the family as a whole is affected by the stressors associated with the disease and the side effects of treatment, being inevitable the alteration of the whole family system, especially in cases where the patient is a infant or adolescent. In addition, it is necessary to underline that studies indicate that most of the care of adolescent patients generally is undertaken by one specific member of the family, usually called the main caregiver. The stress due to the care tasks has been associated with anxiety and depression symptoms, often causing emotional disturbances in the caregivers, associating the above with greater emotional symptomatology in adolescents and worse control of their disease. That's why more studies like the one proposed are needed to study more deeply the protective factors of psychological and physical health during the course of chronic disease at this stage of life, both in the adolescent patients as well as in their family. The main aim of this research is to study the psychosocial factors, adjustment to the disease and improvement of psychological well-being in the adolescent population with chronic disease. In order to do this, the investigators are going to analyse the main characteristics (psychological, family related and adjustment to disease) in the adolescent population with endocrinological problems (short stature and diabetes mellitus type 1), respiratory (asthma) and allergenic problems. These characteristics will also be analysed in the family of the adolescent patients. The personal adaptation profiles and families features that favor the psychological and physical health in these patients and their family caregivers will be also identified. In addition, the investigators also propose as an aim the development and implementation of an assessment and intervention program (in a pilot sample) that provides socio-emotional education in adolescent patients with chronic disease and their family caregivers.


Recruitment information / eligibility

Status Completed
Enrollment 500
Est. completion date December 30, 2023
Est. primary completion date December 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Years to 16 Years
Eligibility Inclusion Criteria: - Diagnosis at least 6 months. - To have signed the informed consent. Exclusion Criteria: - No previous psychological diagnosis. - Attention Deficit Hyperactivity Disorder(ADHD), epilepsy or brain tumor - Infant cerebral palsy - Not understanding the Spanish language

Study Design


Intervention

Other:
Ten Vida (10Vida)
10Vida is a psychoeducational and emotional programme for chronic illness in adolescents and their families.

Locations

Country Name City State
Spain University of Valencia Valencia

Sponsors (4)

Lead Sponsor Collaborator
University of Valencia Hospital Clínico Universitario de Valencia, Hospital General Universitario de Valencia, Hospital Universitario La Fe

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Other Glycaemic control (Baseline-Pre-Post) HbA1c: It will be used to evaluate the glycemic control of the diabetic patient in endocrinology diseases Baseline up to 12 months
Other Weight (Baseline-Pre-Post) Kilograms For assessment of nutritional status Baseline up to 12 months
Other Height (Baseline-Pre-Post) Meters For assessment of nutritional status Baseline up to 12 months
Other Body mass index (BMI) (Baseline-Pre-Post) BMI in kg/m^2, for assessment of nutritional status Baseline up to 12 months
Other Spirometry values (Baseline-Pre-Post) All values obtained are expressed as volume (in ml). The main spirometric parameters recorded are forced vital capacity (FVC), vital capacity (VC), peak expired air volume in the first second (FEV1) and peak expiratory flow (PEF). Baseline up to 12 months
Other Blood test ( Baseline-Pre-Post) For monitoring nutritional status (blood concentration of protein, lipids, fat-soluble vitamins, iron and calcium-phosphorus metabolism) and blood concentration of c) glucose metabolism d) acute phase reactants and immune status (immunoglobulins, alpha1 antitrypsin, and e) hepatic and renal functions.) exocrine pancreatic function
• glucose metabolism d) acute phase reactants and immune status (immunoglobulins, alpha1 antitrypsine)
Baseline up to 12 months
Other Exocrine pancreatic test ( Baseline-Pre-Post) For monitoring pancreatic test, faecal elastase and steatorrhoea, and hepatic and renal functions. Baseline up to 12 months
Primary Change Emotional Distress in caregivers (Baseline-Pre-Post) Assessment with Hospital Anxiety and Depression Scale in caregivers (HADS): Screening instrument for the detection of affective disorders, in non-psychiatric subjects who go to hospitals. The scale is made up of 14 items, with a range of scores from 0 to 42. The interpretation is that the higher the score, the greater the presence of anxiety-depressive symptoms.
First measurement: Once the participant had signed the informed consent, the initial score for this outcome was assessed.
Second measurement: PRE- Up to 6 months after the first measurement the second measurement of the same variable was carried out.
Third measurement: POST Up to 6 months after the second measurement the third measurement of the same variable was carried out.
Baseline up to 12 months
Primary Change Emotional Distress in patients (Baseline-Pre-Post) Assessment with Hospital Anxiety and Depression Scale in patients (HADS): Screening instrument for the detection of affective disorders, in non-psychiatric subjects who go to hospitals. The adaptation for this sample, it is made up of 11 items, with a range of scores from 0 to 33. The interpretation is that the higher the score, the greater the presence of anxiety-depressive symptoms.
First measurement: Once the participant had signed the informed consent, the initial score for this outcome was assessed.
Second measurement: PRE- Up to 6 months after the first measurement the second measurement of the same variable was carried out.
Third measurement: POST Up to 6 months after the second measurement the third measurement of the same variable was carried out.
Baseline up to 12 months
Primary Change Caregiver burden (Baseline-Pre-Post) Assessment with Parental Inventory: It aims to assess the stress of parents with children who require regular medical attention. It consists of 12 situations related to the hospital environment that are considered potentially stressful for parents with sick children. The range of scores is 12 to 60. And it is interpreted like higher scores, higher levels of stress.
First measurement: Once the participant had signed the informed consent, the initial score for this outcome was assessed.
Second measurement: PRE- Up to 6 months after the first measurement the second measurement of the same variable was carried out.
Third measurement: POST Up to 6 months after the second measurement the third measurement of the same variable was carried out.
Baseline up to 12 months
Primary Change Emotional competences in patients (Baseline-Pre-post) Emotional Skills and Competence Questionnaire (ESCQ-21): this is a self-report measure developed by Takšic to assess emotional competence. In the present study, the reduced version (ESCQ-21) was used, adapted and validated in a Spanish sample by Schoeps et al. The aim of assessing is emotional competence: perception and comprehension, expressing and labeling and management and regulation) Baseline up to 12 months
Primary Change Self-esteem in patients (Baseline-Pre-Post) Rosenberg Self-Esteem Questionnaire. It assesses the level of self-esteem. It is made up Baseline up to 12 months
Primary Change of Perceived level of disease threat (Baseline-Pre-Post) Brief Disease Perception Questionnaire (B-IPQ): This is a measure of patients' cognitive Baseline up to 12 months
Secondary Change Resilience in caregivers (Baseline-Pre-Post) Connor-Davidson Resilience Scale to assess the ability to cope with stress and adversity. The resilience scale is made up of 10 items, with a range of scores from 0 to 40, with higher scores indicating greater resilience.
First measurement: Once the participant had signed the informed consent, the initial score for this outcome was assessed.
Second measurement: PRE- Up to 6 months after the first measurement the second measurement of the same variable was carried out.
Third measurement: POST Up to 6 months after the second measurement the third measurement of the same variable was carried out.
Baseline up to 12 months
Secondary Change of Adaptation to chronic disease (DM1) (Baseline-Pre-Post) Adaptive response questionnaire to the disease in diabetic patients: with the aim of evaluating the elements involved in the psychological and social response in pediatric diabetic patients. This instrument includes cognitive, emotional and behavioural elements that may be related to the adjustment response to the disease. The lower the score, the more severe the disease, the worse the health behaviour, the various complaints associated with the disease.
First measurement: Once the participant had signed the informed consent, the initial score for this outcome was assessed.
Second measurement: PRE- Up to 6 months after the first measurement the second measurement of the same variable was carried out.
Third measurement: POST Up to 6 months after the second measurement the third measurement of the same variable was carried out.
Baseline up to 12 months
Secondary Change of Adaptation to chronic disease (Respiratory chronic diseases) (Baseline-Pre-Post This questionnaire evaluates health-related quality of life in relation to chronic respiratory problems. It is made up of 4 dimensions: sensation of dyspnea, sensation of fatigue, emotional symptomatology and disease control.
The total score is obtained by adding up the score in each of the dimensions and dividing by 4. The resulting evaluation ranges from 1 (maximum affectation of up to 7 (no affectation) First measurement: Once the participant had signed the informed consent, the initial score for this outcome was assessed.
Second measurement: PRE- Up to 6 months after the first measurement the second measurement of the same variable was carried out.
Third measurement: POST Up to 6 months after the second measurement the third measurement of the same variable was carried out.
Baseline up to 12 months
Secondary Change of Adaptation to chronic disease (Rhinoconjunctivitis) (Baseline-Pre-Post) It is a specific quality of life assessment instrument for the pediatric population with rhinoconjunctivitis. It aims to obtain a measure of the impact that allergic symptoms have on patients' daily functioning, and not only the severity and frequency. All items are weighted equally and a higher score is indicative of a poorer quality of life.
First measurement: Once the participant had signed the informed consent, the initial score for this outcome was assessed.
Second measurement: PRE- Up to 6 months after the first measurement the second measurement of the same variable was carried out.
Third measurement: POST Up to 6 months after the second measurement the third measurement of the same variable was carried out.
Baseline up to 12 months
Secondary Change of Adaptation to chronic disease (Food Allergy)(Baseline-Pre-Post) Quality of Life Questionnaire in Food Allergy (FAQLQ- TF) It assessed quality of life relation with food allergy. The range of scores is from 0 to 6. The interpretation of the scores is reversed, i.e. the lower the score, the better the perceived quality of life.
First measurement: Once the participant had signed the informed consent, the initial score for this outcome was assessed.
Second measurement: PRE- Up to 6 months after the first measurement the second measurement of the same variable was carried out.
Third measurement: POST Up to 6 months after the second measurement the third measurement of the same variable was carried out.
Baseline up to 12 months
Secondary Change in family functioning in caregivers (Baseline-Pre-Post) Family Functioning Questionnaire (CAF) based on Olson's model. It was created with the aim of constructing a measuring instrument to evaluate the variables that make up the dynamics of a family Baseline up to 12 months
Secondary Change in parental styles in patients (Baseline-Pre-Post) Scale for the evaluation of the educational style of parents of adolescents (EP). It allows evaluating the perception that adolescents have of the educational style of their parents. Baseline up to 12 months
Secondary Change Psychological well-being (Baseline-Pre-Post) Psychological well-being scale for adolescents (BIEPS-J) to determine the level of psychological well-being in adolescents Baseline up to 12 months
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device